Abstract: It is intended to provide a kit or a device for the detection of esophageal cancer and a method for detecting esophageal cancer. The present invention provides a kit or a device for the detection of esophageal cancer, comprising nucleic acid(s) capable of specifically binding to miRNA(s) in a sample of a subject, and a method for detecting esophageal cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
November 18, 2022
Date of Patent:
June 18, 2024
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: The present invention provides methods for detecting donor cell-free DNA in the circulation of an organ transplant recipient for the early identification of transplant rejection.
Abstract: Methods are described for the efficient and accurate detection of bladder cancer. In particular, the method utilizes microsatellite analysis of bladder cancer markers to determine the presence of loss of heterozygosity or microsatellite instability using matched buccal swab and urine samples from a patient. In some cancer marker panels, detected loss of heterozygosity or microsatellite instability in two markers can be indicative of bladder cancer.
Abstract: An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
October 31, 2022
Date of Patent:
April 16, 2024
Assignees:
Toray Industries, Inc., National Cancer Center
Abstract: A highly accurate non-invasive prenatal testing methodology that allows accurate fetal rhesus determination and fetal DNA fraction measurement in a single assay is provided. The disclosed testing may be administered as early as at week 10 of pregnancy and can be conveniently combined with prenatal genetic disease testing and detection.
Abstract: The present disclosure provides methods of treating subjects having obesity and/or increased body mass index (BMI), and methods of identifying subjects having an increased risk of developing obesity and/or BMI.
Type:
Grant
Filed:
August 13, 2021
Date of Patent:
March 26, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Luca Andrea Lotta, Parsa Akbari, Manuel Allen Revez Ferreira, Aris Baras
Abstract: This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.
Abstract: Provided herein are methods and systems pertaining to sequencing units of analytes using nanopores. In general, arresting constructs are used to modify an analyte such that the modified analyte pauses in the opening of a nanopore. During such a pause, an ion current level is obtained that corresponds to a unit of the analyte. After altering the modified analyte such that the modified analyte advances through the opening, another arresting construct again pauses the analyte, allowing for a second ion current level to be obtained that represents a second unit of the analyte. This process may be repeated until each unit of the analyte is sequenced. Systems for performing such methods are also disclosed.
Type:
Grant
Filed:
November 24, 2021
Date of Patent:
February 27, 2024
Assignee:
University of Washington
Inventors:
Jens H. Gundlach, Ian M. Derrington, Marcus D. Collins
Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
October 31, 2022
Date of Patent:
February 20, 2024
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
September 14, 2022
Date of Patent:
January 2, 2024
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: Disclosed is a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, including a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, including measuring the miRNA(s) in vitro.
Type:
Grant
Filed:
September 20, 2022
Date of Patent:
January 2, 2024
Assignees:
TORAY INDUSTRIES, LTD., NATIONAL CANCER CENTER
Abstract: Methods and kits for diagnosing or predicting the risk of developing psoriatic arthritis in a subject in need of such diagnosis or risk prediction are provided, comprising measuring the expression level of one or more miRNAs disclosed herein in the sample of the subject, and compared the expression level of at least one of the miRNAs in the test sample with that of the psoriatic arthritis-free sample. Also provided are methods of treating psoriatic arthritis by reducing the expression level of at least one of the miRNAs disclosed herein.
Abstract: Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B3 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.
Type:
Grant
Filed:
January 19, 2018
Date of Patent:
December 19, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Noura S. Abul-Husn, Omri Gottesman, Alexander Li, Xiping Cheng, Yurong Xin, Jesper Gromada, Frederick E. Dewey, Aris Baras, Alan Shuldiner
Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
October 21, 2022
Date of Patent:
November 28, 2023
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: A screening kit for paroxysmal supraventricular tachycardia contains a reagent for detecting a human CACNA1B gene c. 1700A>G mutation site at base No. 1700 in a coding region of CACNA1B gene from A to G.
Type:
Grant
Filed:
September 10, 2020
Date of Patent:
October 24, 2023
Assignees:
SICHUAN PROVINCIAL PEOPLE'S HOSPITAL, CHENGDU MEDICAL COLLEGE, NANJING YSY BIOTECH COMPANY LTD.
Inventors:
Xiaoping Li, Rong Luo, Qingshun Zhao, Zhenglin Yang, Tao He, Mingjiang Liu
Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
Type:
Grant
Filed:
February 17, 2021
Date of Patent:
October 17, 2023
Assignee:
Celera Corporation
Inventors:
Yonghong Li, Steven Schrodi, Ann Begovich, Monica Chang
Abstract: The present disclosure relates to methods of monitoring the status of an allograft in a transplant recipient, as well as to methods of monitoring and adjusting immunosuppressive therapies being administered to the transplant recipient.
Type:
Grant
Filed:
March 13, 2015
Date of Patent:
September 26, 2023
Assignee:
CareDx, Inc.
Inventors:
Robert Woodward, Marica Grskovic, James Yee, Mitch Nelles, David Hiller
Abstract: The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
September 8, 2022
Date of Patent:
September 19, 2023
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: Provided are compositions and methods for identifying a canine suffering from or at risk of suffering from skeletal dysplasia (SD) and/or intervertebral disc disease (IVDD) by detecting a retrogene insertion encoding canine fibroblast growth factor 4 (FGF4) on canine chromosome 12.
Type:
Grant
Filed:
May 23, 2018
Date of Patent:
September 19, 2023
Assignee:
The Regents of the University of California
Inventors:
Danika Bannasch, Emily Brown, Peter J. Dickinson
Abstract: The present invention includes methods and materials for use in the detection preeclampsia and/or determining an increased risk for preeclampsia in a pregnant female, the method including identifying in a biosample obtained from the pregnant women a plurality of circulating RNA (C-RNA) molecules.
Type:
Grant
Filed:
November 20, 2020
Date of Patent:
September 12, 2023
Assignee:
ILLUMINA, INC.
Inventors:
Sarah E. Shultzaberger, Fiona Kaper, Sarah Kinnings, Suzanne Rohrback, Carlo Randise-Hinchliff